Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration

The use of BCR-ABL1 tyrosine kinase inhibitors (TKI) has led to excellent clinical responses in patients with chronic phase chronic myeloid leukemia (CML). However these inhibitors have been less effective as single agents in the terminal blast phase (BP). We show that pyrvinium, a FDA-approved anth...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Wei, Cheong, Jit Kong, Ang, Shi Hui, Teo, Bryan, Xu, Peng, Asari, Kartini, Sun, Wen Tian, Than, Hein, Bunte, Ralph M., Virshup, David M., Chuah, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741801/
https://www.ncbi.nlm.nih.gov/pubmed/26378050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741801/
https://www.ncbi.nlm.nih.gov/pubmed/26378050

Ejemplares similares